Vietnam Bird Flu Vaccine Could Be On Market By End Of 2009
This article was originally published in PharmAsia News
Executive Summary
A Vietnam-developed vaccine to prevent avian influenza could be on the market in mass-produced quantities by the end of next year. The Company for Vaccine and Biological Production No. 1 said the goal depends on human trials set to begin in Vietnam in late March. The Ministry of Health has cleared human trials of the H5N1 vaccine, but the Ministry of Defense, which would supply students of the Military Medical Academy for the trials, has not yet agreed. (Click here for more
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.